PMC7411254_01
PMC7411254_02
The reads of 20 insertion subtypes identified by NGS and Sanger sequencing. (A,C) Patient 4 with G780_P781dupGSP; (B,D) Patient 5 with G778_S779insCPG.
fonc-10-01162-g0001.jpg
PMC7411254_03_fonc-10-01162-g0001.jpg
F1
The result of NGS revealed HER2 insertion mutation (p.G780_P781dupGSP) (Figures 1B,D).
Representative images from chest CT.
fonc-10-01162-g0002.jpg
PMC7411254_03_fonc-10-01162-g0002.jpg
F2
Then the patient took pyrotinib as the third-line therapy with the best response of PR, and PFS was 12.5 months until November 30, 2019 (Figure 2).
PMC7411254_03
The reads of 20 insertion subtypes identified by NGS and Sanger sequencing. (A,C) Patient 4 with G780_P781dupGSP; (B,D) Patient 5 with G778_S779insCPG.
fonc-10-01162-g0001.jpg
PMC7411254_03_fonc-10-01162-g0001.jpg
F1
The result of NGS revealed HER2 insertion mutation (p.G780_P781dupGSP) (Figures 1B,D).
Representative images from chest CT.
fonc-10-01162-g0002.jpg
PMC7411254_03_fonc-10-01162-g0002.jpg
F2
Then the patient took pyrotinib as the third-line therapy with the best response of PR, and PFS was 12.5 months until November 30, 2019 (Figure 2).